Medivizor

Title of notification

Here comes the notification
X
 
icon
icon
prostate cancer | Research | Treatment | 10 pages | source: International journal of radiation oncology, biology, physics | Added Jul 21, 2021

Evaluating hypofractionated radiotherapy after prostate surgery in patients with prostate cancer.

This study investigated the outcomes of hypofractionated intensity-modulated radiation therapy (H-IMRT) to the prostate bed in patients with localized prostate cancer after prostate surgery. The data showed that H-IMRT after prostate surgery was safe and well-tolerated in these patients.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Journal of Urology | Added Jul 18, 2021

Comparing darolutamide with apalutamide and enzalutamide for treating non-metastatic castration-resistant prostate cancer.

The study compared the effectiveness and safety outcomes of darolutamide (Nubeqa) with apalutamide (Erleada) and enzalutamide (Xtandi) in treating non-metastatic castration-resistant prostate cancer (CRPC). The data showed that darolutamide was safer and had similar effectiveness compared to apalutamide and enzalutamide.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Jul 16, 2021

Comparing docetaxel to abiraterone in patients with metastatic castration-sensitive prostate cancer

This study compared the effectiveness of docetaxel (DOC; Taxotere) to abiraterone (ABI; Zytiga) and assessed possible predictive markers of progression-free survival (PFS) in patients with metastatic castration-sensitive prostate cancer (mCSPC). The authors concluded that under real-world conditions, ABI was associated with better PFS in these patients.

icon
prostate cancer | Research | 10 pages | source: Cancer | Added Jul 14, 2021

Does androgen-deprivation therapy increase risk of mortality from heart attack or stroke?

This study examined the risk of heart-related mortality in patients undergoing androgen-deprivation therapy (ADT) for prostate cancer. It found that patients treated with radiation therapy and ADT did not have an increased risk of heart-related mortality.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Jun 30, 2021

Evaluating the effectiveness of salvage radiotherapy for recurrence after prostate surgery in patients with localized prostate cancer.

This study evaluated the effectiveness of salvage radiotherapy (RT) in patients with recurrence of prostate cancer (PCa) after prostate surgery. The study found that salvage RT was effective in the management of PCa recurrence with manageable side effects.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Journal of clinical oncology | Added Jun 27, 2021

Evaluating the long-term outcomes of apalutamide plus androgen deprivation therapy in metastatic castration-sensitive prostate cancer

This study reported the long-term effectiveness and safety outcomes of apalutamide (Erleada) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). The data showed that this combination improved survival, delayed castration resistance, and maintained the quality of life in these patients.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: World Journal of Urology | Added Jun 06, 2021

Comparing the outcomes of robot‑assisted and laparoscopic radical prostatectomy for the treatment of localized prostate cancer.

This study compared the outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer. The study found that the RARP approach was associated with better outcomes compared to LRP.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: European Urology | Added May 30, 2021

Analyzing the effectiveness and safety of Lutetium-177–labeled PSMA–targeted therapy in patients with metastatic castration-resistant prostate cancer.

This study reviewed the effectiveness and safety of lutetium-177 [177Lu]-prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (PRLT) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that PRLT was associated with good outcomes and manageable side effects.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: Cancer Treatment Reviews | Added May 16, 2021

Evaluating the effectiveness and safety a second radiation therapy in patients with prostate cancer.

This study investigated the effectiveness and safety of re-irradiation in the treatment of patients with relapsed prostate cancer (PCa). The data showed that the use of re-irradiation in these patients was associated with good outcomes and low toxicity.

icon
icon
prostate cancer | Research | Treatment | 10 pages | source: BJU international | Added May 06, 2021

Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.

This study compared the outcomes of Retzius-sparing (RS) robotic-assisted laparoscopic prostatectomy (RALP) with standard RALP (sRALP) for the treatment of patients with localized prostate cancer (PCa). The study found that the RS-RALP approach may be associated with better urinary outcomes compared to sRALP.

View

Category

  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon
  • icon

Was this helpful?